NASDAQ:AKAO - Achaogen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.78 -0.05 (-0.42 %)
(As of 05/23/2018 10:49 AM ET)
Previous Close$11.97
Today's Range$11.78 - $12.04
52-Week Range$9.83 - $26.50
Volume13,404 shs
Average Volume1.54 million shs
Market Capitalization$529.04 million
P/E Ratio-3.76
Dividend YieldN/A
Beta1.02

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636

Debt

Debt-to-Equity Ratio0.24
Current Ratio7.01
Quick Ratio7.01

Price-To-Earnings

Trailing P/E Ratio-3.76
Forward P/E Ratio-3.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.18 million
Price / Sales47.20
Cash FlowN/A
Price / CashN/A
Book Value$2.30 per share
Price / Book5.12

Profitability

EPS (Most Recent Fiscal Year)($3.17)
Net Income$-125,610,000.00
Net Margins-2,384.08%
Return on Equity-97.86%
Return on Assets-62.39%

Miscellaneous

Employees230
Outstanding Shares44,800,000

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen (NASDAQ:AKAO) released its quarterly earnings data on Friday, May, 4th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.17. The biopharmaceutical company earned $2.14 million during the quarter, compared to analysts' expectations of $1.25 million. Achaogen had a negative return on equity of 97.86% and a negative net margin of 2,384.08%. View Achaogen's Earnings History.

What price target have analysts set for AKAO?

9 analysts have issued 12-month price objectives for Achaogen's stock. Their forecasts range from $16.00 to $29.00. On average, they anticipate Achaogen's share price to reach $22.1250 in the next twelve months. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:
  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (5/9/2018)
  • 2. Mizuho analysts commented, "We are reducing our PT from $28 to $20 based on a worst-case scenario analysis assuming no revenues from BSI or any other potential usages and an additional capital raise of $200 million in 2019 (an amount we see as adequate to carry the company to break-even point). We would be buyers on weakness as we believe Achaogen has an approvable drug in cUTI and there could be upside potential from Plazomicin in Carbapenem- resistant enterobacteriaceae (CRE) cases over time." (5/3/2018)
  • 3. Needham & Company LLC analysts commented, "Plazomicin will be discussed at an FDA Advisory Committee (AdCom) mtg 5/2/18. Achaogen completed two Phase 3 trials, a standard cUTI trial (EPIC) and the other a descriptive trial in patients with HABP/VABP or bloodstream infections caused by Carbapenem Resistant Enterobacteriaceae (CRE; CARE). Both trials had positive outcomes, w/ the latter surprisingly demonstrating superiority to comparator colistin. Achaogen is seeking a label in both cUTI and Bloodstream infections, although Bloodstream is controversial given the descriptive nature of the CARE trial. The Avycaz and Cresemba AdCom mtgs are most relevant to analysis of the plazomicin mtg and we have a modest bias towards a vote in favor of including both indications on plazomicin label. Our note details recent antibiotic FDA reviews and individual voting histories. BUY." (4/30/2018)
  • 4. HC Wainwright analysts commented, "We find no big surprises in the FDA analyses. This morning, FDA released its Briefing Document for the May 2, 2018 meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) to review the NDA for Achaogen’s plazomicin for the proposed indications for the treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis (AP); and bloodstream infections (BSI), in adults." (4/30/2018)

Are investors shorting Achaogen?

Achaogen saw a increase in short interest in April. As of April 30th, there was short interest totalling 14,173,240 shares, an increase of 13.5% from the April 13th total of 12,483,137 shares. Based on an average trading volume of 1,389,113 shares, the days-to-cover ratio is presently 10.2 days. Approximately 55.9% of the company's stock are short sold.

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:
  • Mr. Blake Wise, CEO & Director (Age 47)
  • Dr. Kenneth J. Hillan, Pres of R&D, Pres of Achaogen and Director (Age 57)
  • Dr. Floyd E. Romesberg Ph.D., Principal Scientific Founder and Advisor
  • Dr. Nathaniel E. David A.B., Ph.D., Principal Entrepreneurial Founder (Age 50)
  • Mr. Tobin C. Schilke, Chief Financial Officer & Principal Accounting Officer (Age 43)

Has Achaogen been receiving favorable news coverage?

Media coverage about AKAO stock has trended somewhat negative on Wednesday, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Achaogen earned a coverage optimism score of -0.19 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Achaogen's major shareholders?

Achaogen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.47%), Prosight Management LP (1.48%), UBS Group AG (0.66%), Candriam Luxembourg S.C.A. (0.50%), Gabelli Funds LLC (0.39%) and Fiera Capital Corp (0.37%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Which major investors are selling Achaogen stock?

AKAO stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Kenneth J Hillan and Tobin Schilke. View Insider Buying and Selling for Achaogen.

Which major investors are buying Achaogen stock?

AKAO stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, RMB Capital Management LLC, Gabelli Funds LLC, Prosight Management LP, Gamco Investors INC. ET AL, BlackRock Inc., Engineers Gate Manager LP and Candriam Luxembourg S.C.A.. Company insiders that have bought Achaogen stock in the last two years include Equity Opportunities Iv Growth and Robert W Duggan. View Insider Buying and Selling for Achaogen.

How do I buy shares of Achaogen?

Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of AKAO stock can currently be purchased for approximately $11.78.

How big of a company is Achaogen?

Achaogen has a market capitalization of $529.04 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (AKAO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achaogen (NASDAQ:AKAO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Achaogen in the last 12 months. Their average twelve-month price target is $22.1250, suggesting that the stock has a possible upside of 87.82%. The high price target for AKAO is $29.00 and the low price target for AKAO is $16.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.893.002.902.89
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.1250$23.1250$25.4444$25.6250
Price Target Upside: 87.82% upside110.23% upside131.73% upside82.77% upside

Achaogen (NASDAQ:AKAO) Consensus Price Target History

Price Target History for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018GuggenheimDowngradeBuy ➝ Neutral$17.00HighView Rating Details
5/4/2018SunTrust BanksLower Price TargetBuy$16.00HighView Rating Details
5/3/2018MizuhoReiterated RatingBuyHighView Rating Details
4/30/2018Needham & Company LLCReiterated RatingBuy$20.00HighView Rating Details
4/30/2018HC WainwrightReiterated RatingBuy$19.00 ➝ $29.00HighView Rating Details
3/4/2018Leerink SwannReiterated RatingOutperformLowView Rating Details
2/28/2018William BlairReiterated RatingOutperformHighView Rating Details
2/28/2018Stifel NicolausLower Price TargetBuy ➝ Buy$27.00 ➝ $23.00MediumView Rating Details
2/14/2018WedbushReiterated RatingPositive ➝ Outperform$28.00 ➝ $22.00HighView Rating Details
5/15/2017CowenReiterated RatingOutperformN/AView Rating Details
3/30/2017AegisDowngradeBuy ➝ Hold$29.00LowView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Achaogen (NASDAQ:AKAO) Earnings History and Estimates Chart

Earnings by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.66)
2019 EPS Consensus Estimate: ($3.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.00)($0.85)($0.93)
Q2 20183($1.03)($0.95)($1.00)
Q3 20184($0.95)($0.77)($0.87)
Q4 20184($0.92)($0.81)($0.86)
Q1 20191($0.90)($0.90)($0.90)
Q2 20191($0.86)($0.86)($0.86)
Q3 20191($0.84)($0.84)($0.84)
Q4 20191($0.80)($0.80)($0.80)

Achaogen (NASDAQ AKAO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2018Q1 2018($0.89)($1.06)$1.25 million$2.14 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.77)($0.98)$1.18 million$1.87 millionViewListenView Earnings Details
11/8/2017Q3($0.72)($0.85)$2.09 million$0.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.60)($0.66)$5.21 million$5.85 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Achaogen (NASDAQ:AKAO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 72.92%
Insider Trading History for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2018Robert W DugganMajor ShareholderBuy976,880$11.33$11,068,050.408,027,627View SEC Filing  
4/27/2018Robert W DugganMajor ShareholderBuy102,849$12.96$1,332,923.047,028,153View SEC Filing  
4/25/2018Robert W DugganMajor ShareholderBuy77,247$13.02$1,005,755.947,028,153View SEC Filing  
4/23/2018Robert W DugganMajor ShareholderBuy468,337$13.06$6,116,481.226,602,269View SEC Filing  
4/19/2018Robert W DugganMajor ShareholderBuy119,700$12.76$1,527,372.006,602,269View SEC Filing  
4/4/2018Robert W DugganMajor ShareholderBuy47,361$12.44$589,170.846,411,108View SEC Filing  
4/2/2018Robert W DugganMajor ShareholderBuy20,000$12.51$250,200.006,411,108View SEC Filing  
3/28/2018Robert W DugganMajor ShareholderBuy30,000$12.44$373,200.006,391,108View SEC Filing  
3/20/2018Robert W DugganMajor ShareholderBuy36,300$11.12$403,656.006,336,108View SEC Filing  
3/15/2018Robert W DugganMajor ShareholderBuy49,660$11.36$564,137.606,294,808View SEC Filing  
3/13/2018Kenneth J. HillanInsiderSell2,735$11.74$32,108.90View SEC Filing  
3/12/2018Robert W DugganMajor ShareholderBuy20,000$11.39$227,800.006,255,148View SEC Filing  
3/9/2018Robert W DugganMajor ShareholderBuy50,000$11.41$570,500.006,255,148View SEC Filing  
3/2/2018Robert W DugganMajor ShareholderBuy527,396$10.31$5,437,452.765,697,752View SEC Filing  
2/28/2018Robert W DugganMajor ShareholderBuy20,000$10.70$214,000.005,697,752View SEC Filing  
2/21/2018Blake WiseCEOSell1,640$10.67$17,498.80View SEC Filing  
2/21/2018Kenneth J. HillanInsiderSell4,606$10.67$49,146.02View SEC Filing  
2/21/2018Tobin SchilkeCFOSell1,108$10.67$11,822.36View SEC Filing  
2/14/2018Robert W DugganMajor ShareholderBuy10,000$10.96$109,600.005,668,310View SEC Filing  
1/5/2018Robert W DugganMajor ShareholderBuy50,000$11.51$575,500.005,617,752View SEC Filing  
1/3/2018Robert W DugganMajor ShareholderBuy15,000$10.89$163,350.005,617,752View SEC Filing  
12/18/2017Robert W DugganMajor ShareholderBuy95,012$11.13$1,057,483.565,602,752View SEC Filing  
9/26/2017Blake WiseCOOSell3,576$15.99$57,180.24View SEC Filing  
9/26/2017Gary LoebGeneral CounselSell1,146$15.99$18,324.54View SEC Filing  
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.8432,728View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.8461,628View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achaogen (NASDAQ AKAO) News Headlines

Source:
DateHeadline
Lucky Seven: Bio Struggles, Achaogen Breaks Key SupportLucky Seven: Bio Struggles, Achaogen Breaks Key Support
seekingalpha.com - May 22 at 8:11 AM
$1.49 Million in Sales Expected for Achaogen (AKAO) This Quarter$1.49 Million in Sales Expected for Achaogen (AKAO) This Quarter
www.americanbankingnews.com - May 22 at 2:34 AM
 Brokerages Expect Achaogen (AKAO) Will Post Earnings of -$0.92 Per Share Brokerages Expect Achaogen (AKAO) Will Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - May 20 at 5:14 PM
Achaogen (AKAO) Given Average Recommendation of "Buy" by BrokeragesAchaogen (AKAO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 11:05 AM
Achaogen (AKAO) Insider Lee Swem Sells 900 SharesAchaogen (AKAO) Insider Lee Swem Sells 900 Shares
www.americanbankingnews.com - May 15 at 8:34 PM
Achaogen: Explicating The Prospects Of C-ScapeAchaogen: Explicating The Prospects Of C-Scape
seekingalpha.com - May 13 at 8:09 AM
Wedbush Analysts Increase Earnings Estimates for Achaogen (AKAO)Wedbush Analysts Increase Earnings Estimates for Achaogen (AKAO)
www.americanbankingnews.com - May 11 at 9:50 AM
Achaogen: A Long-Term Holding With Tremendous ProspectsAchaogen: A Long-Term Holding With Tremendous Prospects
seekingalpha.com - May 11 at 8:07 AM
Short Interest in Achaogen (AKAO) Expands By 13.5%Short Interest in Achaogen (AKAO) Expands By 13.5%
www.americanbankingnews.com - May 11 at 3:29 AM
Research Analysts Offer Predictions for Achaogens FY2018 Earnings (AKAO)Research Analysts Offer Predictions for Achaogen's FY2018 Earnings (AKAO)
www.americanbankingnews.com - May 10 at 8:41 AM
Achaogen (AKAO) Upgraded by Zacks Investment Research to "Hold"Achaogen (AKAO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 9 at 5:09 PM
Achaogen (AKAO) Forecasted to Post Q2 2018 Earnings of ($1.03) Per ShareAchaogen (AKAO) Forecasted to Post Q2 2018 Earnings of ($1.03) Per Share
www.americanbankingnews.com - May 9 at 8:39 AM
Leerink Swann Weighs in on Achaogens Q2 2018 Earnings (AKAO)Leerink Swann Weighs in on Achaogen's Q2 2018 Earnings (AKAO)
www.americanbankingnews.com - May 9 at 8:39 AM
Achaogen: In The Middle Of A Temporary Difficulty There Is A Stellar OpportunityAchaogen: In The Middle Of A Temporary Difficulty There Is A Stellar Opportunity
seekingalpha.com - May 9 at 8:07 AM
Editors Notes: Visiting The Achaogen And Axon BattlegroundsEditor's Notes: Visiting The Achaogen And Axon Battlegrounds
seekingalpha.com - May 8 at 5:52 PM
Robert W. Duggan Buys 976,880 Shares of Achaogen (AKAO) StockRobert W. Duggan Buys 976,880 Shares of Achaogen (AKAO) Stock
www.americanbankingnews.com - May 7 at 7:20 PM
Achaogen After Ad CommAchaogen After Ad Comm
seekingalpha.com - May 7 at 5:47 PM
Achaogen (AKAO) Stock Rating Lowered by GuggenheimAchaogen (AKAO) Stock Rating Lowered by Guggenheim
www.americanbankingnews.com - May 7 at 2:58 PM
SunTrust Banks Comments on Achaogens FY2019 Earnings (AKAO)SunTrust Banks Comments on Achaogen's FY2019 Earnings (AKAO)
www.americanbankingnews.com - May 7 at 5:04 AM
Achaogen (AKAO) Expected to Post Q1 2019 Earnings of ($0.88) Per ShareAchaogen (AKAO) Expected to Post Q1 2019 Earnings of ($0.88) Per Share
www.americanbankingnews.com - May 7 at 4:38 AM
Edited Transcript of AKAO earnings conference call or presentation 4-May-18 12:30pm GMTEdited Transcript of AKAO earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 5 at 5:55 PM
Achaogen (AKAO) Issues  Earnings ResultsAchaogen (AKAO) Issues Earnings Results
www.americanbankingnews.com - May 5 at 1:33 PM
 Analysts Anticipate Achaogen (AKAO) Will Announce Quarterly Sales of $1.25 Million Analysts Anticipate Achaogen (AKAO) Will Announce Quarterly Sales of $1.25 Million
www.americanbankingnews.com - May 5 at 4:21 AM
Achaogen (AKAO) Given New $16.00 Price Target at SunTrust BanksAchaogen (AKAO) Given New $16.00 Price Target at SunTrust Banks
www.americanbankingnews.com - May 4 at 10:31 PM
My Favorite Investment For The Coming Biotech Bull Market (Bret Jensen)My Favorite Investment For The Coming Biotech Bull Market (Bret Jensen)
seekingalpha.com - May 4 at 8:08 AM
Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old DataYour Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data
seekingalpha.com - May 4 at 8:08 AM
BRIEF-Achaogen Q1 loss per share $1.06BRIEF-Achaogen Q1 loss per share $1.06
www.reuters.com - May 4 at 8:08 AM
Rounds Report: Eleven Train Heads Further North While Achaogen Gained Mixed ADCOM ResultsRounds Report: Eleven Train Heads Further North While Achaogen Gained Mixed ADCOM Results
seekingalpha.com - May 4 at 8:08 AM
Unjustified Sell-Off In Achaogen After FDA Panel Vote Provides A Golden OpportunityUnjustified Sell-Off In Achaogen After FDA Panel Vote Provides A Golden Opportunity
seekingalpha.com - May 4 at 8:08 AM
Achaogen: 1Q Earnings SnapshotAchaogen: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:08 AM
Mizuho Reiterates "Buy" Rating for Achaogen (AKAO)Mizuho Reiterates "Buy" Rating for Achaogen (AKAO)
www.americanbankingnews.com - May 3 at 12:06 PM
Why Achaogen Shares Are Getting Crushed On Plazomicin FDA NewsWhy Achaogen Shares Are Getting Crushed On Plazomicin FDA News
feeds.benzinga.com - May 3 at 11:37 AM
Achaogen (AKAO) Expected to Post Earnings of -$0.91 Per ShareAchaogen (AKAO) Expected to Post Earnings of -$0.91 Per Share
www.americanbankingnews.com - May 3 at 10:17 AM
BRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract InfectionsBRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract Infections
www.reuters.com - May 3 at 8:06 AM
AKAO Slumps On FDA Panel Vote, ESPR Awaits Data In May, STAA ShinesAKAO Slumps On FDA Panel Vote, ESPR Awaits Data In May, STAA Shines
www.nasdaq.com - May 3 at 8:06 AM
Peninsula drug developer's stock plunges, but its antibiotic still could win FDA approvalPeninsula drug developer's stock plunges, but its antibiotic still could win FDA approval
finance.yahoo.com - May 3 at 8:06 AM
Why the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public CompanyWhy the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public Company
finance.yahoo.com - May 3 at 8:06 AM
Achaogen (AKAO) Scheduled to Post Earnings on FridayAchaogen (AKAO) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - May 2 at 8:15 PM
Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with ...Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with ...
globenewswire.com - May 2 at 5:45 PM
Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract InfectionsAchaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections
finance.yahoo.com - May 2 at 5:45 PM
Achaogen (AKAO) Lifted to "Hold" at BidaskClubAchaogen (AKAO) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 2 at 1:07 PM
Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus ...Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus ...
globenewswire.com - May 2 at 8:11 AM
Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus, and First Defiance Financial — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus, and First Defiance Financial — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - May 2 at 8:11 AM
Achaogen Stock Trading Halted TodayAchaogen Stock Trading Halted Today
finance.yahoo.com - May 2 at 8:11 AM
Achaogen shares halted pending outcome of Ad Com reviewAchaogen shares halted pending outcome of Ad Com review
seekingalpha.com - May 2 at 8:04 AM
Achaogen (AKAO) Lowered to "Sell" at Zacks Investment ResearchAchaogen (AKAO) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 1 at 6:06 PM
Investors Purchase High Volume of Put Options on Achaogen (AKAO)Investors Purchase High Volume of Put Options on Achaogen (AKAO)
www.americanbankingnews.com - May 1 at 7:16 AM
Options Traders Expect Huge Moves in Achaogen (AKAO) StockOptions Traders Expect Huge Moves in Achaogen (AKAO) Stock
www.zacks.com - April 30 at 5:21 PM
Premarket Gainers as of 9:05 am (04/30/2018)Premarket Gainers as of 9:05 am (04/30/2018)
seekingalpha.com - April 30 at 5:21 PM
Achaogen (AKAO) on Watch After FDA Posts Briefing Documents for PlazomicinAchaogen (AKAO) on Watch After FDA Posts Briefing Documents for Plazomicin
www.streetinsider.com - April 30 at 5:21 PM

SEC Filings

Achaogen (NASDAQ:AKAO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achaogen (NASDAQ AKAO) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.